Chicago, Illinois
Phase 1 cancer trials in Chicago, IL
102 Phase 1 cancer studies are recruiting participants at sites in Chicago as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Chicago at a glance
- 102 studies are recruiting at a site in Chicago.
- By phase: Early Phase 1 (5), Phase 1 (50), Phase 1/2 (47).
- By sponsor: industry (72), university, hospital or other (24), government (6).
- By research area: Lymphoma (34), Breast Cancer (28), Lung Cancer (22), Prostate Cancer (7), Pancreatic Cancer (6), Melanoma (5).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Chicago
Basic details from each study's public record (the 30 most recently updated of 102). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Totus Medicines
- Study site
- Northwestern Memorial Hospital
- Registry record
- NCT05683418 · updated
A Phase 1/2 Study of IAM1363 in HER2 Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- University of Chicago
- Registry record
- NCT06253871 · updated
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Stemline Therapeutics, Inc.
- Study sites
- University of Chicago Medical Center · University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)
- Registry record
- NCT06638307 · updated
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Phase 1
- Ages 18 to 55
- Female participants
- Sponsor
- TerSera Therapeutics LLC
- Study site
- University of Illinois at Chicago
- Registry record
- NCT07310420 · updated
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- University of Illinois Hospital & Health Sciences System
- Registry record
- NCT06827236 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Northwestern University
- Registry record
- NCT05315700 · updated
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- University of Chicago Hospital
- Registry record
- NCT06465069 · updated
Study of XB010 in Subjects With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- University of Chicago Medical Center
- Registry record
- NCT06545331 · updated
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Study site
- UChicago Medicine Comprehensive Cancer Center
- Registry record
- NCT06908928 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Lung cancer studies recruiting in Chicago
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Vivace Therapeutics, Inc
- Study site
- University of Chicago Medical Center
- Registry record
- NCT04665206 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT06287775 · updated
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
- Phase 1
- Ages 6 to 17
- All sexes
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Study site
- Ann & Robert H. Lurie Children's Hospital
- Registry record
- NCT06235125 · updated
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BlossomHill Therapeutics
- Study site
- Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion
- Registry record
- NCT06706076 · updated
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Synthekine
- Study site
- University of Chicago
- Registry record
- NCT05098132 · updated
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Alentis Therapeutics AG
- Study site
- The University of Chicago Medical Center - Oncology
- Registry record
- NCT06747585 · updated
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- University of Chicago
- Study site
- University of Chicago Medicine Comprehensive Cancer Center
- Registry record
- NCT07782359 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Prostate cancer studies recruiting in Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Genentech, Inc.
- Study site
- University of Illinois Hospital & Health Sciences System
- Registry record
- NCT05800665 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- University of Chicago Medical Center
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Melanoma studies recruiting in Chicago
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Phase 1/2
- From 6 months, up to 17 years
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Call for Information (Investigational Site 0024)
- Registry record
- NCT02332668 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Chicago, IL on ClinicalTrials.gov.
Lymphoma studies recruiting in Chicago
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study sites
- Lurie Children's Hospital-Chicago · University of Chicago Comprehensive Cancer Center · University of Illinois
- Registry record
- NCT04726241 · updated
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Debiopharm International SA
- Study site
- Northwestern Memorial Hospital
- Registry record
- NCT05765812 · updated
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Phase 1
- Ages 0 to 18
- All sexes
- Sponsor
- Autolus Limited
- Study site
- Lurie Children's Hospital
- Registry record
- NCT06173518 · updated
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07109219 · updated
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Chicago Comprehensive Cancer Center
- Registry record
- NCT05272384 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- University of Chicago Medical Center
- Registry record
- NCT05384626 · updated
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- The University of Chicago Medical Center (UCMC)
- Registry record
- NCT07101328 · updated
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
- Early Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- AIDS Malignancy Consortium
- Study site
- University of Illinois at Chicago
- Registry record
- NCT04139304 · updated
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT06015880 · updated
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- University of Illinois Chicago
- Study site
- University of Illinois at Chicago
- Registry record
- NCT07647432 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Chicago, IL on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Chicago
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Northwestern University
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Chicago, IL on ClinicalTrials.gov.
Ask about studies near Chicago
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections